Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

EAST HANOVER, N.J., Dec. 2, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

The CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), held from December 6-10, will feature data presentations from Phase III studies of Afinitor® (everolimus) tablets for investigational uses and Zometa® (zoledronic acid) 4mg/5mL Injection, as well as early-stage studies of the investigational drug BKM120, an inhibitor of PI3K, a key cancer pathway(1).

The American Society of Hematology (ASH) annual meeting in San Diego, held from December 10-13, will showcase key data for Tasigna® (nilotinib), Exjade® (deferasirox) and the investigational drug INC424 (ruxolitinib)(*). Several early-stage studies will also be presented, including everolimus in Hodgkin lymphoma and Waldenstrom's macroglobulinemia and LBH589 (panobinostat) in relapsed and bortezomib (BTZ)-refractory multiple myeloma(2).

"These important data are examples of our research and development strategy to focus on significant unmet medical needs by targeting the fundamental mechanisms of disease," said Herve Hoppenot, President, Novartis Oncology. "Through our collaborations with the scientific and patient communities, we continue to advance our goal of transforming patients' lives."

Highlights at SABCS include:

  • Everolimus – Updated data from the BOLERO-2 (Breast cancer trials of OraL EveROlimus) Phase III trial of everolimus in combination with exemestane for postmenopausal women with ER+HER2- advanced breast cancer who recurred or progressed while on or following previous treatment with the hormonal therapies letrozole or anastrozole (S
    '/>"/>

  • SOURCE Novartis Pharmaceuticals Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

    Related biology technology :

    1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
    2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
    3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
    4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
    5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
    6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
    7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
    8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
    9. Novartis Class Awarded $250 Million in Punitive Damages
    10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
    11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/27/2015)... The Medical Innovation Impact Index (MI3), a ... medical innovation, has been developed at the Initiative ... University’s ( FDU ) Rothman Institute of Innovation and ... new FDA (Food & Drug Administration) draft guidance documents ... certain medical devices. , “The main impediment to ...
    (Date:5/26/2015)... May 26, 2015 Innovacyn, a ... in the human and animal health industries, announced ... Future Innovators of Agriculture College Scholarship Award. The ... who exhibits a passionate commitment to the agriculture ... This year’s winners, Alexis Pedrow from Anderson County ...
    (Date:5/26/2015)... May 26, 2015  Alere Inc. (NYSE: ALR ) ... failure to timely file its Quarterly Report on Form 10-Q ... 10-Q"), it has received a notice from the New York ... compliance with the NYSE,s continued listing requirements under the timely ... Company Manual. The reason for the delay ...
    (Date:5/26/2015)... WORTH, Texas , May 26, 2015  A ... Texas Health Science Center to detect early Alzheimer,s disease ... older adults. Detailed standardized guidelines that are ... practice have been published in Alzheimer,s & Dementia ... efforts of an international working group that includes UNT ...
    Breaking Biology Technology:Medical Innovation Impact Index Launched at Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) under the Rothman Institute 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 3Guidelines bring UNT Health Science Center's blood test for Alzheimer's one step closer 2
    ... July 27 ... optimize clinical trial enrollment for life sciences companies, is ... 100 award based on their successful deployment of DecisionView ... is a web-based patient enrollment optimization solution that automates ...
    ... July 27 All signs point to accelerated growth in ... explosion of demand for services, central government policy continues to urge greater ... on Wednesday, September 8 , executives and managers can learn how ... , , , ...
    ... July 27 Article One Partners, the world,s ... $5 million round of institutional funding with Alleghany ... SE: Y), and other investors. The funding will be used ... online patent validation sector by enhancing existing products and services, ...
    Cached Biology Technology:Pfizer Wins CIO 100 Award for Patient Enrollment Optimization Solution From DecisionView 2Orchestrall Sponsors 'China Business Toolbox': Brings Focus to the 'How and When' of China Market Access 2Orchestrall Sponsors 'China Business Toolbox': Brings Focus to the 'How and When' of China Market Access 3Article One Announces Completion of Funding from Alleghany Corporation 2Article One Announces Completion of Funding from Alleghany Corporation 3
    (Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
    (Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
    (Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
    Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
    ... largest ever to have taken place in a large ... HIV, and is the first study of this kind ... been coordinated by Javier Martínez-Picado, ICREA research professor in ... and Josep M. Miró, consultant of the Unit of ...
    ... binds to a neuron, how does the cell know to ... with other questions involving good sensations, the answer appears to ... appearing with a commentary in Nature Neuroscience online proposes a ... in the cell membrane and brings news of nicotine’s arrival. ...
    ... wild squash. The length of the day relative to ... induction of flowering in many plant species. Short day (SD) ... long night) in order to flower. These are plants that ... fall in temperate regions. Long day (LD) plants will flower ...
    Cached Biology News:Identified main genetic variants involved in response to HIV 2Nicotine rush hinges on sugar in neurons 2Research identifies protein that signals flowering in squash plants 2Research identifies protein that signals flowering in squash plants 3
    Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
    Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
    Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
    Human Siglec-9 Biotinylated Affinity Purified Pab...
    Biology Products: